Skip to content
Open access

TEgment dissects transposable element reactivation upon CDK9 inhibition in acute myeloid leukemia

Sep 2026 · bioRxiv · 0 citations · 96 references
Biology

TL;DR

TEgment, a TE-centric RNA-sequencing analysis pipeline, provides a versatile framework for resolving TE transcriptional modalities at locus and structural levels, enabling precise interpretation of TE-derived transcripts in cancer and other contexts.

Abstract

Cyclin-dependent kinase 9 (CDK9) inhibition represents a promising therapeutic strategy in cancers that disrupts RNA polymerase II pause release and collapses oncogenic transcripts. Here, we show that CDK9 inhibition also induces widespread transposable element (TE) activation across diverse cancer types. In acute myeloid leukemia (AML), CDK9 inhibition induces rapid epigenetic reprogramming and robust TE upregulation. To dissect this non-canonical transcriptional response, we developed TEgment, a TE-centric RNA-sequencing analysis pipeline that classifies TE expression into distinct structural modalities: standalone, readthrough, protein-coding gene-embedded (5′UTR, coding exons, and 3′UTRs), lncRNA-embedded, intron-retained, and TE-initiated/terminated transcription events. Applying TEgment to CDK9-inhibited AML revealed that TEs are predominantly expressed as readthrough, 3’UTR-embedded, and lncRNA-embedded transcripts rather than autonomous units, challenging prevailing assumptions about TE reactivation. TEgment provides a versatile framework for resolving TE transcriptional modalities at locus and structural levels, enabling precise interpretation of TE-derived transcripts in cancer and other contexts. Highlights CDK9 inhibition induces widespread TE expression across diverse cancer models AML cells show rapid, transient TE induction coupled to epigenetic reprogramming TEgment classifies TE-derived transcripts into structural modalities TEgment reveals predominant activation of TEs embedded within host transcripts upon CDK9 inhibition

Read PDF

Similar papers

Oct 2026

Transposable element splicing reveals a tumor-enriched class of gene-independent transcripts.

Transposable elements (TEs) are broadly reactivated in tumors, but their repetitive nature has limited transcript-level characterization. Here, we systematically investigate the TE-derived splicing landscape across pan-cancer samples and define a splice-resolved subset of TE-derived transcripts, termed TEtrans, with tu...

Zi-Teng Li, Yi-Chao Bao, Hong-Wu Yu et al. · 0 citations
Review Open access Sep 2026

Hypertranscription: the invisible hand in cancer epigenetics

Global upregulation of transcription, or hypertranscription, is observed in most human cancers, driven by the action of oncogene-encoded transcription factors (TFs). TF interactions with RNA Polymerase II (Pol II) are mediated by kinases that phosphorylate the Pol II C-terminal domain (CTD) to drive productive elonga...

S. Henikoff, Robert N. Eisenman, K. Ahmad · 0 citations
Open access Oct 2026

Comprehensive characterization of transposable element expression reveals regulatory circuitry and clinical implications in cancers

Transposable elements (TEs) constitute nearly half of the human genome and have crucial roles in regulatory networks and clinical utility in cancers. However, the expression profiles at a single-element resolution remain unexplored. By integrating multiomics data from ∼10,000 samples and 1000 cancer cell lines, we esta...

Wei Hu, Wen-Jun Jiang, Ze-Hua Gao et al. · 0 citations
Open access Sep 2026

AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness.

These findings enrich and extend the understanding of AML1-ETO regulatory programs by linking distal enhancer activity to a NAT10-GSTO2 ac4C-GSH axis that integrates epigenomic, posttranscriptional, and metabolic reprogramming to sustain LSC stemness.

Shuyi Li, Shu-Jiao He, Yongwei Su et al. · 0 citations
Review Open access Sep 2026

Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer

Extrachromosomal DNA (ecDNA) has emerged as a major contributor to cancer aggressiveness, yet its role extends far beyond its classical definition as a vehicle for oncogene amplification. Recent studies indicate that ecDNA functions as a dynamic regulatory platform that reshapes chromatin accessibility, enhancer activi...

Bi-Xia Liu, Lu-Yuan Zhou, Shu-Zhen Lai et al. · 0 citations
2027

Epigenetic Analysis in Ewing Sarcoma.

Ornella Urzì, Tamina Stelzer, Jason Sims et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.